Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PDL BioPharma Seeks Ularitide Partner That Grants Rights To A Late-Stage Drug

This article was originally published in The Pink Sheet Daily

Executive Summary

A more complicated partnership involving two clinical programs is taking more time to complete than a “ularitide-only” deal, the biotech says.

You may also be interested in...



PDL BioPharma Product Sales Up 25 Percent On Cardene Growth

Firm is focused on lifecycle management for Cardene as well as partnering opportunities for investigational drugs ularitide and Nuvion, CEO says.

PDL BioPharma Product Sales Up 25 Percent On Cardene Growth

Firm is focused on lifecycle management for Cardene as well as partnering opportunities for investigational drugs ularitide and Nuvion, CEO says.

Biogen Idec/PDL BioPharma Plan To Study Daclizumab As Monotherapy For MS

Phase II monotherapy trial for the monoclonal antibody will initiate in the second half of 2007, PDL tells “The Pink Sheet” DAILY.

Related Content

Topics

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel